S&P 500   3,771.43 (-0.51%)
DOW   30,203.93 (-0.37%)
QQQ   281.05 (-0.38%)
AAPL   145.80 (-0.21%)
MSFT   248.33 (-0.22%)
META   138.18 (-1.50%)
GOOGL   100.81 (-0.82%)
AMZN   120.62 (-0.39%)
TSLA   239.06 (-4.16%)
NVDA   130.90 (-0.58%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.59 (-0.46%)
T   15.92 (-1.06%)
MU   54.53 (+1.06%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.58 (+0.06%)
DIS   99.98 (-1.44%)
AMC   7.32 (-6.51%)
PYPL   93.77 (+1.06%)
PFE   44.09 (-0.83%)
NFLX   233.92 (-2.83%)
S&P 500   3,771.43 (-0.51%)
DOW   30,203.93 (-0.37%)
QQQ   281.05 (-0.38%)
AAPL   145.80 (-0.21%)
MSFT   248.33 (-0.22%)
META   138.18 (-1.50%)
GOOGL   100.81 (-0.82%)
AMZN   120.62 (-0.39%)
TSLA   239.06 (-4.16%)
NVDA   130.90 (-0.58%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.59 (-0.46%)
T   15.92 (-1.06%)
MU   54.53 (+1.06%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.58 (+0.06%)
DIS   99.98 (-1.44%)
AMC   7.32 (-6.51%)
PYPL   93.77 (+1.06%)
PFE   44.09 (-0.83%)
NFLX   233.92 (-2.83%)
S&P 500   3,771.43 (-0.51%)
DOW   30,203.93 (-0.37%)
QQQ   281.05 (-0.38%)
AAPL   145.80 (-0.21%)
MSFT   248.33 (-0.22%)
META   138.18 (-1.50%)
GOOGL   100.81 (-0.82%)
AMZN   120.62 (-0.39%)
TSLA   239.06 (-4.16%)
NVDA   130.90 (-0.58%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.59 (-0.46%)
T   15.92 (-1.06%)
MU   54.53 (+1.06%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.58 (+0.06%)
DIS   99.98 (-1.44%)
AMC   7.32 (-6.51%)
PYPL   93.77 (+1.06%)
PFE   44.09 (-0.83%)
NFLX   233.92 (-2.83%)
S&P 500   3,771.43 (-0.51%)
DOW   30,203.93 (-0.37%)
QQQ   281.05 (-0.38%)
AAPL   145.80 (-0.21%)
MSFT   248.33 (-0.22%)
META   138.18 (-1.50%)
GOOGL   100.81 (-0.82%)
AMZN   120.62 (-0.39%)
TSLA   239.06 (-4.16%)
NVDA   130.90 (-0.58%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.59 (-0.46%)
T   15.92 (-1.06%)
MU   54.53 (+1.06%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.58 (+0.06%)
DIS   99.98 (-1.44%)
AMC   7.32 (-6.51%)
PYPL   93.77 (+1.06%)
PFE   44.09 (-0.83%)
NFLX   233.92 (-2.83%)
Positive News Sentiment  
NASDAQ:ALBO

Albireo Pharma - ALBO Stock Forecast, Price & News

$19.55
+0.04 (+0.21%)
(As of 10/5/2022 01:47 PM ET)
Add
Compare
Today's Range
$19.10
▼
$19.60
50-Day Range
$16.32
▼
$26.37
52-Week Range
$16.02
▼
$37.63
Volume
6,753 shs
Average Volume
576,124 shs
Market Capitalization
$383.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.25

Albireo Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
172.0% Upside
$53.25 Price Target
Short Interest
Bearish
11.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$48,983 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.95) to ($6.05) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

532nd out of 1,087 stocks

Pharmaceutical Preparations Industry

250th out of 546 stocks

See Top Rated MarketRank™ Stocks Here
ALBO stock logo

About Albireo Pharma (NASDAQ:ALBO) Stock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock News Headlines

October 5, 2022 | finance.yahoo.com
Albireo to Showcase New Data at AASLD The Liver Meeting® 2022
September 26, 2022 | americanbankingnews.com
Robert W. Baird Raises Albireo Pharma (NASDAQ:ALBO) Price Target to $43.00
October 5, 2022 | Investing Trends (Ad)
GRAPHITE: "Essential for America's National Defense"
Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider.
September 24, 2022 | fool.com
Albireo Pharma, Inc. (NASDAQ: ALBO)
September 22, 2022 | marketwatch.com
Albireo Pharma Shares Rise After Royalty Agreement
September 22, 2022 | finance.yahoo.com
Albireo Announces $115 Million Royalty Monetization Agreement with Sagard
September 20, 2022 | finance.yahoo.com
Albireo to Participate in Guggenheim Nantucket Therapeutics Conference
September 8, 2022 | msn.com
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
October 5, 2022 | Investing Trends (Ad)
GRAPHITE: "Essential for America's National Defense"
Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider.
September 7, 2022 | finanznachrichten.de
Albireo Pharma, Inc.: Italian Medicines Agency Approves Reimbursed Access to Bylvay (odevixibat) For Patients with All PFIC Types
September 6, 2022 | finance.yahoo.com
Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat) For Patients with All PFIC Types
August 30, 2022 | nasdaq.com
Albireo Pharma To Announce ALGS Trial Data This Fall
August 25, 2022 | nasdaq.com
Albireo Pharma, Inc. (NASDAQ:ALBO) Analysts Are Reducing Their Forecasts For This Year
August 16, 2022 | benzinga.com
Recap: Albireo Pharma Q2 Earnings
August 16, 2022 | seekingalpha.com
Albireo Pharma stock slips ~26% after co cuts FY sales guidance for lead drug Bylvay
August 16, 2022 | finance.yahoo.com
Albireo Reports Q2 2022 Financial Results and Business Update
August 12, 2022 | finance.yahoo.com
Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
August 11, 2022 | finance.yahoo.com
Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?
August 10, 2022 | finance.yahoo.com
Albireo Appoints New Members to Board of Directors
August 3, 2022 | finance.yahoo.com
Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference
August 1, 2022 | finance.yahoo.com
Albireo to Report Q2 2022 Financial Results on August 15, 2022
July 25, 2022 | finance.yahoo.com
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
July 6, 2022 | finance.yahoo.com
The Lancet Gastroenterology & Hepatology Publishes Data from Albireo’s Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC
June 30, 2022 | finance.yahoo.com
Albireo to Present at the William Blair Biotech Focus Conference 2022
June 28, 2022 | finance.yahoo.com
Albireo Pharma, Inc. (NASDAQ:ALBO): When Will It Breakeven?
June 23, 2022 | finance.yahoo.com
Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases
June 8, 2022 | finance.yahoo.com
Albireo to Present New Data at the EASL International Liver Congress™ 2022
See More Headlines
Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Company Calendar

Last Earnings
8/15/2022
Today
10/05/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALBO
CUSIP
N/A
CIK
1322505
Web
www.albireopharma.com
Phone
(857) 254-5555
Fax
203-796-5001
Employees
130
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$53.25
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+172.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-34,030,000.00
Net Margins
-70.79%
Pretax Margin
-70.79%
Return on Equity
-76.19%
Return on Assets
-43.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.49
Quick Ratio
4.44

Sales & Book Value

Annual Sales
$40.58 million
Price / Sales
9.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.11 per share
Price / Book
2.15

Miscellaneous

Outstanding Shares
19,610,000
Free Float
18,260,000
Market Cap
$383.38 million
Optionable
Optionable
Beta
0.82

Social Links


Key Executives

  • Mr. Ronald H. W. Cooper (Age 59)
    CEO, Pres & Director
    Comp: $1.1M
  • Mr. Simon Nicolas Reade Harford (Age 61)
    CFO & Treasurer
    Comp: $687.78k
  • Ms. Martha J. Carter (Age 70)
    Chief Regulatory Officer
    Comp: $710.69k
  • Dr. Per-Goran Gillberg Ph.D.
    Co-Founder & VP of Devel.
  • Dr. Jan P. Mattsson Ph.D. (Age 58)
    Chief Scientific Officer, MD (Sweden) & Co-Founder
  • Ms. Joan Connolly
    Chief Technology Officer
  • Mr. Jason G. DuncanMr. Jason G. Duncan (Age 48)
    Chief Legal Officer, Gen. Counsel & Sec.
  • Ms. Michelle Graham (Age 55)
    Chief HR Officer
  • Dr. Kristina Torfgard
    VP & Global Project Head
  • Ms. Pamela Stephenson M.P.H.Ms. Pamela Stephenson M.P.H. (Age 54)
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ALBO Stock - Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALBO shares.
View ALBO analyst ratings or view top-rated stocks.

What is Albireo Pharma's stock price forecast for 2022?

4 brokers have issued 12-month price objectives for Albireo Pharma's shares. Their ALBO share price forecasts range from $43.00 to $61.00. On average, they expect the company's stock price to reach $53.25 in the next twelve months. This suggests a possible upside of 177.5% from the stock's current price.
View analysts price targets for ALBO or view top-rated stocks among Wall Street analysts.

How have ALBO shares performed in 2022?

Albireo Pharma's stock was trading at $23.29 at the beginning of the year. Since then, ALBO stock has decreased by 17.6% and is now trading at $19.19.
View the best growth stocks for 2022 here.

When is Albireo Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ALBO earnings forecast.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) announced its earnings results on Monday, August, 15th. The biopharmaceutical company reported ($2.04) earnings per share for the quarter, missing the consensus estimate of ($1.58) by $0.46. The biopharmaceutical company had revenue of $8.21 million for the quarter, compared to analysts' expectations of $9.42 million. Albireo Pharma had a negative net margin of 70.79% and a negative trailing twelve-month return on equity of 76.19%. During the same period in the previous year, the business earned ($1.90) EPS.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

How do I buy shares of Albireo Pharma?

Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $19.19.

How much money does Albireo Pharma make?

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $376.32 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does Albireo Pharma have?

The company employs 130 workers across the globe.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.